Literature DB >> 1405394

[Perforating keratoplasty in endogenous eczema. An indication for systemic cyclosporin A--a retrospective study of 18 patients].

T Reinhard1, R Sundmacher.   

Abstract

Endogenous eczema represents a considerable risk for perforating keratoplasty because of the associated chronic surface disorders and complex immunological disturbances. Between December 1986 through October 1991 we performed 24 perforating keratoplasties in 20 eyes of 18 patients with endogenous eczema suffering from keratokonus, atopic keratokonjunctivitis and bullous keratopathy after intracapsular cataract extraction. During the follow-up period of 16 (3-48) months 6 transplants failed mostly due to surface problems as well as immune reactions and bacterial transplant infections. Systemically administered ciclosporin A was found to eliminate many of the previously unsolved problems. In summary, 18 out of 20 eyes achieved an improved visual acuity with clear transplants.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1405394     DOI: 10.1055/s-2008-1045885

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  6 in total

1.  Use of cyclosporin in the treatment of steroid resistant post-keratoplasty atopic sclerokeratitis.

Authors:  M D Daniell; J K Dart; S Lightman
Journal:  Br J Ophthalmol       Date:  2001-01       Impact factor: 4.638

Review 2.  [Systemic immunosuppressives after penetrating keratoplasty].

Authors:  A Reis; F Birnbaum; T Reinhard
Journal:  Ophthalmologe       Date:  2007-05       Impact factor: 1.059

3.  Clear graft survival and immune reactions following emergency keratoplasty.

Authors:  P Maier; D Böhringer; T Reinhard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-06       Impact factor: 3.117

Review 4.  [Ocular allergies].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

5.  [Significance of cyclosporin A absorption for effective immunomodulatory therapy after high-risk keratoplasty].

Authors:  N Bailly; I Dunewa; P Schlattmann; P W Rieck
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

Review 6.  [Ocular involvement in atopic dermatitis : Clinical aspects and therapy].

Authors:  P Maier; T Lapp; T Reinhard
Journal:  Ophthalmologe       Date:  2017-06       Impact factor: 1.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.